Benzocaine gels and liquids are sold OTC under different brand names such as Anbesol (Wyeth), Hurricaine, Orajel (Del), Baby Orajel (Del), Orabase, and store brands.įor more information visit /Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm250264.htm. Benzocaine sprays are marketed under different brand names such as Hurricaine, Cetacaine, Exactacain, and Topex. Healthcare professionals are advised to consider the American Academy of Pediatrics’ recommendations for treating teething pain instead of using the benzocaine teething products.īenzocaine is available as a spray, used during medical procedures to numb the mucous membranes of the mouth and throat, and in gel and liquid formulations sold over-the-counter (OTC) for the relief of teething, canker sores, and irritation of the mouth and gums. Benzocaine products should not be used on children <2 years of age, except under the advice and supervision of a healthcare professional. Infants <4 months of age, elderly patients, and patients with certain inborn defects such as glucose-6-phosphodiesterase deficiency, hemoglobin-M disease, NADH-methemoglobin reductase (diaphorase 1) deficiency, and pyruvate-kinase deficiency may also be at greater risk of developing methemoglobinemia. This dose is often exceeded and an overdose. Healthcare professionals should advise patients and caregivers to use the smallest amount possible to relieve pain. Benzocaine topical spray allows for the safe application of the drug with a usual maximum of two 1-second puffs. Symptoms of methemoglobinemia may appear within minutes to one or two hours after using benzocaine. A review of the cases indicates that the development of methemoglobinemia after treatment with benzocaine sprays may not be related to the amount applied. Since then, the FDA has received 72 new cases of methemoglobinemia, including three resulting in death, associated with the use of benzocaine sprays, bringing the total to 319 cases. In 2006, FDA issued a Public Health Advisory warning about methemoglobinemia with the use of benzocaine sprays during medical procedures. The FDA notified healthcare professionals and patients that it has continued to receive reports of methemoglobinemia associated with benzocaine products.
0 kommentar(er)
